EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant

Shumpei Onishi, Masato Kojima, Fumiyuki Yamasaki, Vishwa Jeet Amatya, Ushio Yonezawa, Akira Taguchi, Iori Ozono, Yukari Go, Yukio Takeshima, Eiso Hiyama, Nobutaka Horie

Neurosurgical Review · 2024

DOI: 10.1007/s10143-024-02632-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Review, 2024. Verfasst von Shumpei Onishi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, 734-855…. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms, Isocitrate Dehydrogenase, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The WHO classification of central nervous system tumors (5th edition) classified astrocytoma, IDH-mutant accompanied with CDKN2A/B homozygous deletion as WHO grade 4. Loss of immunohistochemical (IHC) staining for methylthioadenosine phosphorylase (MTAP) was developed as a surrogate marker for CDKN2A-HD. Identification of imaging biomarkers for CDKN2A status is of immense clinical relevance. In this study, we explored the association between radiological characteristics of non-enhancing astrocytoma, IDH-mutant to the CDKN2A/B status.

Methods

Thirty-one cases of astrocytoma, IDH-mutant with MTAP results by IHC were included in this study. The status of CDKN2A was diagnosed by IHC staining for MTAP in all cases, which was further confirmed by comprehensive genomic analysis in 12 cases. The T2-FLAIR mismatch sign, cystic component, calcification, and intratumoral microbleeding were evaluated. The relationship between the radiological features and molecular pathological diagnosis was analyzed.

Results

Twenty-six cases were identified as CDKN2A-intact while 5 cases were CDKN2A-HD. The presence of > 33% and > 50% T2-FLAIR mismatch was observed in 23 cases (74.2%) and 14 cases (45.2%), respectively, and was associated with CDKN2A-intact astrocytoma ( p = 0.0001, 0.0482). None of the astrocytoma, IDH-mutant with CDKN2A-HD showed T2-FLAIR mismatch sign. Cystic component, calcification, and intratumoral microbleeding were not associated with CDKN2A status.

Conclusion

In patients with non-enhancing astrocytoma, IDH-mutant, the T2-FLAIR mismatch sign is a potential imaging biomarker for the CDKN2A-intact subtype. This imaging biomarker may enable preoperative prediction of CDKN2A status among astrocytoma, IDH-mutant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaBrain NeoplasmsIsocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16MutationHumansMaleFemaleMiddle AgedAdultAgedMagnetic Resonance ImagingPurine-Nucleoside PhosphorylaseBiomarkers, TumorYoung Adult

Stichwörter der Autor:innen

AstrocytomaCDKN2A homozygous deletionGliomaIDH-mutantT2-FLAIR mismatch sign

Substanzen

Isocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16CDKN2A protein, human5'-methylthioadenosine phosphorylasePurine-Nucleoside PhosphorylaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, 734-8551, Hiroshima, Japan.
  • Department of Pediatric Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan.
  • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, 734-8551, Hiroshima, Japan. fyama@hiroshima-u.ac.jp.
  • Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Medical Division Technical Center, Hiroshima University, Hiroshima, Japan.

Förderung

  • Hiroshima University

Zitieren

APA

Onishi, S., Kojima, M., Yamasaki, F., Amatya, V. J., Yonezawa, U., Taguchi, A., Ozono, I., Go, Y., Takeshima, Y., Hiyama, E., & Horie, N. (2024). T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant. Neurosurgical Review. https://doi.org/10.1007/s10143-024-02632-5

Vancouver

Onishi S, Kojima M, Yamasaki F, Amatya VJ, Yonezawa U, Taguchi A, et al. T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant. Neurosurgical Review. 2024. doi:10.1007/s10143-024-02632-5

BibTeX
@article{Onishi2024,
  author = {Onishi, Shumpei and Kojima, Masato and Yamasaki, Fumiyuki and Amatya, Vishwa Jeet and Yonezawa, Ushio and Taguchi, Akira and Ozono, Iori and Go, Yukari and Takeshima, Yukio and Hiyama, Eiso and Horie, Nobutaka},
  title = {T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant},
  journal = {Neurosurgical Review},
  year = {2024},
  doi = {10.1007/s10143-024-02632-5}
}
Kostenlos starten →